Cadth 2015 b7 crosbie

Scientific Advice

ProgramSupporting the Generation of High Quality Evidence

David Crosbie, Program LeadScientific Advice

2

About the Scientific Advice Program

Voluntary, fee-for-service consultation for pharmaceutical companies

Advice on early drug development plans from a health technology assessment perspective

Advice at an early point in the drug development process

3

About the Scientific Advice Program

Independence

Confidentiality

4

www.cadth.ca/scientificadvice

5

6

7

8

9

Eligibility

New drug products

Existing drug products with new indications

Drugs for rare diseases

Subsequent entry biologics (SEBs)

Oncology products

10

Patient Involvement

11

Benefits for patients

Early input in drug development process

Stronger recommendations based on better evidence

12

Benefits for pharmaceutical companies

Reduced uncertainty

Test new development strategies

Advice in context

13

Benefits for CADTH

Influence evidence generated

Early knowledge of methodologies and approaches

14

www.cadth.ca/scientificadvice

scientificadvice@cadth.ca

requests@cadth.ca

15